Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yasunori Kohchi is active.

Publication


Featured researches published by Yasunori Kohchi.


Bioorganic & Medicinal Chemistry Letters | 2000

Synthesis and structure-activity relationships of novel fungal chitin synthase inhibitors.

Kazunao Masubuchi; Mikio Taniguchi; Isao Umeda; Kazuo Hattori; Hitomi Suda; Yasunori Kohchi; Yoshiaki Isshiki; Toshiya Sakai; Masami Kohchi; Michio Shirai; Hisafumi Okabe; Masayuki Sudoh; Toshikazu Yamazaki; Nobuo Shimma

A novel Candida albicans chitin synthase 1 (CaChs1) inhibitor, RO-41-0986 (1) was discovered by random screening. Systematic modification led to the identification of a highly potent CaChs1 inhibitor, RO-09-3024 (2), having strong antifungal activity against Candida spp. in vitro.


Bioorganic & Medicinal Chemistry Letters | 2003

Design and Synthesis of the Tumor-Activated Prodrug of Dihydropyrimidine Dehydrogenase (DPD) Inhibitor, RO0094889 for Combination Therapy with Capecitabine

Kazuo Hattori; Yasunori Kohchi; Nobuhiro Oikawa; Hitomi Suda; Masako Ura; Tohru Ishikawa; Masanori Miwa; Mika Endoh; Hiroyuki Eda; Hiromi Tanimura; Akira Kawashima; Ikuo Horii; Hideo Ishitsuka; Nobuo Shimma

A series of tumor-activated prodrugs of the inhibitors of dihydropyrimidine dehydrogenase (DPD), an enzyme catabolizing 5-fluorouracil (5-FU: 4g), has been designed and synthesized. RO0094889 (11c) is a prodrug of 5-vinyluracil (4c), a known DPD inhibitor, and was designed to generate 4c selectively in tumor tissues by sequential conversion of 11c by three enzymes: esterase, cytidine deaminase and thymidine phosphorylase, the latter two of which are known to be highly expressed in various tumor tissues. When capecitabine (1), a tumor-activated prodrug of 5-FU, was co-administered orally with 11c, 5-FU in tumor tissues was significantly increased with only a slight increase of 5-FU in plasma as compared with oral capecitabine alone.


Bioorganic & Medicinal Chemistry | 2000

The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, Capecitabine

Nobuo Shimma; Isao Umeda; Motohiro Arasaki; Chikako Murasaki; Kazunao Masubuchi; Yasunori Kohchi; Masanori Miwa; Masako Ura; Noriaki Sawada; Hitoshi Tahara; Isamu Kuruma; Ikuo Horii; Hideo Ishitsuka


Archive | 2004

4-Phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (mek) inhibitors

Yoshiaki Isshiki; Yasunori Kohchi; Kazuo Hattori; Nobuo Shimma; Masanori Miwa; Naohito Inagaki; Hitoshi Iikura; Yasuaki Matsubara


Archive | 1998

5'-deoxy-cytidine derivatives

Kazuo Hattori; Tohru Ishikawa; Hideo Ishitsuka; Yasunori Kohchi; Nobuhiro Oikawa; Nobuo Shimma; Hitomi Suda


Archive | 2000

5'-deoxy-cytidine derivative administration to treat solid tumors

Kazuo Hattori; Tohru Ishikawa; Hideo Ishitsuka; Yasunori Kohchi; Nobuhiro Oikawa; Nobuo Shimma; Hitomi Suda


Archive | 1999

5'-deoxycytidine derivatives.

Kazuo Hattori; Tohru Ishikawa; Hideo Ishitsuka; Yasunori Kohchi; Nobuhiro Oikawa; Nobuo Shimma; Hitomi Suda


Archive | 2006

Process for production of 2,3,4-trifluoro-5-(iodo or bromo)benzoic acid

Hiroshi Koyano; Hitoshi Iikura; Yoshiaki Isshiki; Yasunori Kohchi


Archive | 2006

Verfahren zur herstellung von 2,3,4-trifluor-5-(iod- oder -brom)benzoesäure Process for the preparation of 2,3,4-trifluoro-5- (iodo or bromo) benzoic acid

Hiroshi Koyano; Hitoshi Iikura; Yoshiaki Isshiki; Yasunori Kohchi


Archive | 2005

Mek阻害物質としての5-置換-2-フェニルアミノ-ベンズアミド類

Yoshiaki Isshiki; Yasunori Kohchi; Eisaku Mizuguchi; Hitoshi Iikura; Yasuaki Matsubara; Shinji Tsujii; Nobuo Shimma; Masanori Miwa; Satoshi Aida; Masami Kohchi; Takeshi Murata; Kosuke Aso

Collaboration


Dive into the Yasunori Kohchi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nobuo Shimma

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hitoshi Iikura

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar

Nobuhiro Oikawa

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Masanori Miwa

Chugai Pharmaceutical Co.

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge